Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Total Liabilities (2017 - 2025)

Aclaris Therapeutics has reported Total Liabilities over the past 9 years, most recently at $57.4 million for Q4 2025.

  • Quarterly results put Total Liabilities at $57.4 million for Q4 2025, down 11.42% from a year ago — trailing twelve months through Dec 2025 was $57.4 million (down 11.42% YoY), and the annual figure for FY2025 was $57.4 million, down 11.42%.
  • Total Liabilities for Q4 2025 was $57.4 million at Aclaris Therapeutics, up from $55.4 million in the prior quarter.
  • Over the last five years, Total Liabilities for ACRS hit a ceiling of $64.8 million in Q4 2024 and a floor of $27.2 million in Q2 2024.
  • Median Total Liabilities over the past 5 years was $53.4 million (2021), compared with a mean of $50.5 million.
  • Biggest five-year swings in Total Liabilities: tumbled 51.25% in 2024 and later skyrocketed 110.68% in 2025.
  • Aclaris Therapeutics' Total Liabilities stood at $53.9 million in 2021, then increased by 5.76% to $57.0 million in 2022, then fell by 29.4% to $40.2 million in 2023, then surged by 61.02% to $64.8 million in 2024, then decreased by 11.42% to $57.4 million in 2025.
  • The last three reported values for Total Liabilities were $57.4 million (Q4 2025), $55.4 million (Q3 2025), and $57.4 million (Q2 2025) per Business Quant data.